FOLH1 and prostate carcinoma: 225Ac has been tested as a PSMA-targeted therapeutic agent, which also targets hK2 (a serine protease expressed by the prostate 80% similar in sequence with PSA) and CD46 (a protein found overexpressed in prostate cancer tissues).